Allogeneic cell therapy and oncology research by Allogene Therapeutics
Allogene Therapeutics targets 1 in 3 LBCL relapses with ALPHA3 trial and MRD testing
Allogene Therapeutics is addressing the significant challenge of relapse in large B-cell lymphoma (LBCL), where approximately one in three patients experience cancer recurrence following ...
Allogene Therapeutics reviews investigational cema-cel use and early ALPHA3 safety data for community outpatients
Allogene Therapeutics draws attention to a key discussion by Targeted Oncology and Dr. Jeff Sharman on early safety findings for its ALPHA3 investigational therapy. The conversation also examines ...
Allogene Therapeutics to present pipeline and strategy update at Jefferies Global Healthcare Conference
Allogene Therapeutics is set to participate in the Jefferies Global Healthcare Conference in New York, where the company will provide an update on its investigational pipeline and corporate ...
Allogene Therapeutics leadership to share new clinical and corporate insights at oncology summit
Allogene Therapeutics is set to participate in the upcoming TD Cowen 7th Annual Oncology Innovation Summit, where its leadership team will provide updates on the company pipeline and corporate ...
Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment
Allogene Therapeutics is advancing its research into allogeneic CAR T therapies through its ALPHA3 clinical trial, focusing on new treatment options for patients with large B-cell lymphoma (LBCL). ...
Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy
Allogene Therapeutics has introduced ALLO-329, an investigational allogeneic CAR T cell therapy designed for autoimmune disease treatment. The therapy leverages proprietary Dagger technology, ...
Allogene Therapeutics releases Q1 corporate update with focus on allogeneic cell therapy progress
Allogene Therapeutics has published its Q1 corporate update, sharing new business milestones and developments for its allogeneic CAR T cell therapy programs. The company emphasized ongoing ...
Allogene Therapeutics to hold quarterly update on cell therapy progress
Allogene Therapeutics has announced it will hold its first quarter 2026 conference call on Wednesday, May 13 at 2:00 p.m. Pacific Time, equivalent to 5:00 p.m. Eastern Time. The session is ...
Allogene Therapeutics ALPHA3 trial explores allogeneic CAR T potential in LBCL treatment
Allogene Therapeutics is advancing research into allogeneic CAR T therapy through its ALPHA3 clinical trial, aiming to transform treatment options for patients with large B-cell lymphoma (LBCL). ...
Allogene Therapeutics spotlights CTO participation in cell therapy innovation forum
Allogene Therapeutics announced that its Chief Technology Officer, Ben Beneski, will participate in a panel discussion focused on advancing next-generation cell-based therapies. The event, ...
Allogene Therapeutics unveils ALLO-329 to target autoimmune disease with allogeneic CAR-T approach
Allogene Therapeutics introduces ALLO-329, an investigational allogeneic CAR-T therapy intended to transform autoimmune disease treatment. Powered by the company’s Dagger technology, ALLO-329 ...
Allogene Therapeutics aims to redefine CAR T therapy with scalable allogeneic approach
Allogene Therapeutics is focusing on advancing its investigational AlloCAR T products to address challenges found in autologous CAR T treatments. The company asserts that its allogeneic platform ...
Allogene Therapeutics VP joins FiercePharmaEngage to drive M and A strategies in allogeneic cell therapy
Allogene Therapeutics announced that Daniel Hunt, Vice President of Corporate and Business Development, is participating at FiercePharmaEngage to engage in discussions around the evolution of ...
Allogene Therapeutics drives international momentum with ALPHA3 trial and targets Q2 2026 screening
Allogene Therapeutics announced the expansion of its pivotal Phase 2 ALPHA3 trial to include South Korea and Australia, bringing the total number of study sites to more than 80 worldwide. This ...
Allogene Therapeutics presents dual CAR-T cell data for high-risk myeloma after BCMA therapy
Allogene Therapeutics is presenting new data on its allogeneic BCMA/CD70 dual CAR-T cells for patients with high-risk multiple myeloma who have previously received BCMA therapy. The company ...
Allogene Therapeutics advances allogeneic CAR T interim results in early LBCL consolidation
Allogene Therapeutics has announced interim results from a futility analysis of its ALPHA3 clinical trial, which evaluates an allogeneic CAR T-cell therapy in first-line large B-cell lymphoma ...
Allogene Therapeutics advances CAR T therapy to expand access for patients
Allogene Therapeutics is making significant progress in CAR T therapy, aiming to transform the standard of care for patients through bold developments in cell therapy. The company is focused on ...
Allogene Therapeutics targets new approach to autoimmune conditions with ALLO-329
Allogene Therapeutics has introduced ALLO-329, an investigational allogeneic CAR-T therapy developed to transform treatment options for autoimmune diseases. Powered by Dagger technology, the ...
Allogene Therapeutics advances ALLO-329 using Dagger technology to target autoimmune disease
Allogene Therapeutics unveils progress on ALLO-329, an investigational off-the-shelf AlloCAR T product aimed at treating autoimmune diseases with its proprietary Dagger technology. The company ...
Allogene Therapeutics signals breakthrough hope for severe autoimmune disease patients
Allogene Therapeutics points to new advances that could bring relief to patients with severe autoimmune diseases after decades of uncertainty. The company highlighted an initiative from its ...
Allogene Therapeutics unveils plans for Virtual Oncology Summit
Allogene Therapeutics is set to participate in Citi’s 2026 Virtual Oncology Leadership Summit on Wednesday, February 18. The company is poised to provide an update on its investigational ...
